Skin and Soft Tissue Infections Due to Nontuberculous Mycobacteria

Misch, Elizabeth Ann; Saddler, Christopher M; Davis, J. Muse

doi:10.1007/s11908-018-0611-3

Cited by 69 publications

(68 citation statements)

References 181 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…NTM infections were also included in the differential diagnosis for this patient. The incidence of cutaneous NTM infections appears to be increasing so it is imperative for clinicians to maintain a high index of suspicion for these pathogens 8. M. mucogenicum is a rapidly growing non-tuberculous mycobacteria (RGM) found ubiquitously in the environment with a predilection for water supplies 9–11.…”

Section: Discussionmentioning

confidence: 99%

Mycobacterium mucogenicumskin and soft tissue infection of the breast mimicking idiopathic granulomatous mastitis

Krueger

Guggina

2019

BMJ Case Rep

View full text Add to dashboard Cite

We present a case of a 28-year-old woman who came to medical attention after noticing a breast mass associated with an overlying eroded plaque of the skin. A core biopsy of the breast mass was negative for malignancy but demonstrated granulomatous inflammatory changes. Acid-fast bacilli and Gomori methenamine-silver stains were negative for microorganisms. The patient was diagnosed with presumptive idiopathic granulomatous mastitis and started on oral steroids. Her symptoms progressed. Tissue culture from a repeat biopsy grew Mycobacterium mucogenicum. The patient responded well to combination oral antimicrobial therapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Mycobacterium mucogenicumskin and soft tissue infection of the breast mimicking idiopathic granulomatous mastitis

Krueger

Guggina

2019

BMJ Case Rep

View full text Add to dashboard Cite

show abstract

“…Der Keim stellt aufgrund seiner Pathogenität eine besondere Herausforderung dar. Zumeist nosokomial und im Rahmen klei-nerer chirurgischer Eingriffe erworben, führt er zu erythematösen Knoten und subkutanen Abszedierungen [25].…”

Section: Introductionunclassified

Kutane nichttuberkulöse Mykobakteriosen

2019

View full text Add to dashboard Cite

ZusammenfassungAtypische Mykobakterien sind eine heterogene Gruppe ubiquitär vorkommender Umwelt-Saprophyten, die zu oberflächlichen und tiefen Hautinfektionen bis hin zu Hautinfektionen mit Systembeteiligung führen können. Die Erreger vermögen nach Bagatellverletzungen in die Haut einzudringen und führen insbesondere bei Immunsupprimierten zu schweren Infektionen. Klinisch werden schnell und langsam wachsende atypische Mykobakterien unterschieden. Für die Dermatologie wichtige Vertreter der langsam wachsenden Mykobakterien sind M. marinum, M. ulcerans und M. haemophilum. M. marinum verursacht das Schwimmbad- bzw. Aquariumgranulom, die in westlichen Industriestaaten häufigste atypische Mykobakteriose der Haut. M. ulcerans ist der Erreger der weltweit häufigsten kutanen atypischen Mykobakteriose und verursacht v. a. in Westafrika das sog. Buruli-Ulkus. M. haemophilum wird besonders bei Immunsupprimierten und bei Kindern mit begleitender zervikaler und perihilärer Lymphadenitis beobachtet. Zu den schnellwachsenden atypischen Mykobakterien gehören M. abscessus, M. chelonae und M. fortuitum. Relevant sind sie insbesondere als Verursacher von kutanen Mykobakteriosen, die in Zusammenhang mit iatrogener Immunsuppression sowie medizinischen und kosmetischen Prozeduren stehen. Das Management von NTM stellt eine besondere Herausforderung dar: Das klinische Erscheinungsbild ist vielfältig, die Diagnostik schwierig und die antibiotische Kombinationstherapie nicht standardisiert.

show abstract

“…The pulmonary disease represents about 80% of infections caused by NTM [ 12 ]. Recent reports suggest that the NTM pulmonary disease is increasing in several parts of the world [ 13 , 14 ]. However, standardized diagnostics and effective treatment protocols for NTM infections are lacking [ 15 ].…”

Section: Introductionmentioning

confidence: 99%

Carbonic Anhydrase Inhibitors as Novel Drugs against Mycobacterial β-Carbonic Anhydrases: An Update on In Vitro and In Vivo Studies

Aspatwar¹,

Winum

Carta

et al. 2018

Molecules

View full text Add to dashboard Cite

Mycobacteria cause a variety of diseases, such as tuberculosis, leprosy, and opportunistic diseases in immunocompromised people. The treatment of these diseases is problematic, necessitating the development of novel treatment strategies. Recently, β-carbonic anhydrases (β-CAs) have emerged as potential drug targets in mycobacteria. The genomes of mycobacteria encode for three β-CAs that have been cloned and characterized from Mycobacterium tuberculosis (Mtb) and the crystal structures of two of the enzymes have been determined. Different classes of inhibitor molecules against Mtb β-CAs have subsequently been designed and have been shown to inhibit these mycobacterial enzymes in vitro. The inhibition of these centrally important mycobacterial enzymes leads to reduced growth of mycobacteria, lower virulence, and impaired biofilm formation. Thus, the inhibition of β-CAs could be a novel approach for developing drugs against the severe diseases caused by pathogenic mycobacteria. In the present article, we review the data related to in vitro and in vivo inhibition studies in the field.

show abstract

Skin and Soft Tissue Infections Due to Nontuberculous Mycobacteria

Cited by 69 publications

References 181 publications

Mycobacterium mucogenicumskin and soft tissue infection of the breast mimicking idiopathic granulomatous mastitis

Mycobacterium mucogenicumskin and soft tissue infection of the breast mimicking idiopathic granulomatous mastitis

Kutane nichttuberkulöse Mykobakteriosen

Carbonic Anhydrase Inhibitors as Novel Drugs against Mycobacterial β-Carbonic Anhydrases: An Update on In Vitro and In Vivo Studies

Contact Info

Product

Resources

About